Repotrectinib Approved for Adults and Children with NTRK-mutated Cancer
The targeted therapy Repotrectinib was approved for solid tumors with certain NTRK mutations, regardless of where the tumors originated. ...
Progress Against Cancer
The targeted therapy Repotrectinib was approved for solid tumors with certain NTRK mutations, regardless of where the tumors originated. ...
The RET inhibitor is now fully approved to treat certain patients with RET fusion-positive thyroid cancers. The U.S. Food...
The first-in-class targeted therapy inhibits telomerase, a cancer-promoting protein active in many cancers. The U.S. Food and Drug Administration...
The CAR T-cell therapy is now approved for some patients with relapsed/refractory mantle cell lymphoma. The U.S. Food and...
The FDA approved the RET inhibitor selpercatinib for children with thyroid cancer and other solid tumors harboring various RET...
Tarlatamab-dlle is the first t-cell engager that uses the bispecific antibody design for a solid tumor. The U.S. Food...
The CAR T-cell therapy received accelerated approval to treat advanced cases of pretreated follicular lymphoma. The U.S. Food and...
Tisotumab vedotin-tftv is approved to treat certain recurrent or metastatic cervical cancers. The U.S. Food and Drug Administration (FDA)...
The FDA approved the BRAF inhibitor tovorafenib for pediatric patients with certain Genetic alterations. The U.S. Food and Drug...
The FDA has approved lutetium Lu 177 dotatate for children 12 years or older with some gastroenteropancreatic neuroendocrine tumors. ...